ANGION BIOMEDICA(US:ANGN)2024-11-13 21:11Financial Performance - Net loss for the three months ended September 30, 2024, was $18,838,000, compared to a net loss of $10,658,000 for the same period in 2023, reflecting a 76.5% increase in losses[19]. - The company reported a comprehensive loss of $18,802,000 for the three months ended September 30, 2024, compared to a comprehensive loss of $10,681,000 for the same period in 2023, an increase of 75.8%[19]. - For the nine months ended September 30, 2024, the company reported a net loss of $37.894 million, compared to a net loss of $26.246 million for the same period in 2023[26]. - The net loss for the three months ended September 30, 2024, was $18.8 million, compared to a net loss of $10.7 million for the same period in 2023, representing a 76.5% increase[154]. - The basic and diluted net loss per share for the three months ended September 30, 2024, was $(1.39), compared to $(1.27) for the same period in 2023[143]. - Net loss for the nine months ended September 30, 2024, was $37.9 million, compared to a net loss of $26.2 million in the same period of 2023[181]. Assets and Liabilities - Total current assets increased to $30,646,000 as of September 30, 2024, compared to $16,348,000 as of December 31, 2023, representing an increase of 87.5%[17]. - Total liabilities rose significantly to $57,374,000 as of September 30, 2024, from $15,773,000 as of December 31, 2023, marking an increase of 264.5%[17]. - The company’s accumulated deficit increased to $180,097,000 as of September 30, 2024, from $142,203,000 as of December 31, 2023, an increase of 26.7%[17]. - The company had an accumulated deficit of $180.1 million as of September 30, 2024[31]. - The company’s total liabilities included a warrant liability of $23.18 million as of September 30, 2024, with no transfers made among the fair value hierarchy levels during the reporting periods[78]. Cash Flow and Financing - Cash and cash equivalents increased to $26,016,000 as of September 30, 2024, from $12,894,000 as of December 31, 2023, a growth of 102.5%[17]. - Net cash used in operating activities for the nine months ended September 30, 2024, was $28.324 million, compared to $22.799 million for the same period in 2023[26]. - The company reported a net increase in cash and cash equivalents of $13.726 million for the nine months ended September 30, 2024[26]. - Net cash provided by financing activities for the nine months ended September 30, 2024, was $42.1 million, resulting from various financing activities including a $19.7 million convertible note issuance[187]. - The company expects to finance operations through the sale of common stock or other securities, debt financings, or strategic collaborations[190]. Research and Development - Research and development expenses for the nine months ended September 30, 2024, were $22,947,000, up from $17,692,000 in the same period of 2023, indicating a 29.5% increase[19]. - Research and development expenses for the three months ended September 30, 2024, were $7.2 million, a decrease of 1% from $7.3 million in the same period of 2023[172]. - The company incurred $2.2 million in research and development expenses related to a grant agreement for the nine months ended September 30, 2024[92]. - The clinical pipeline includes ELI-002, ELI-007, and ELI-008, targeting specific oncogenic driver mutations, with ELI-002 currently in a Phase 2 clinical program[153]. Stock and Equity - The weighted average common shares outstanding for the three months ended September 30, 2024, were 13,582,345, compared to 8,376,384 for the same period in 2023, an increase of 62.5%[19]. - The company’s additional paid-in capital rose to $161,355,000 as of September 30, 2024, from $153,827,000 as of December 31, 2023, an increase of 4.9%[17]. - The total number of outstanding stock options increased to 1,860,954 as of September 30, 2024, with a weighted average exercise price of $15.87[111]. - The total unrecognized compensation expense related to unvested stock option awards was $3.5 million, expected to be recognized over approximately 2.43 years[112]. - The company has authorized 300 million shares of common stock and 10 million shares of preferred stock as per its current Amended and Restated Certificate of Incorporation[95]. Merger and Acquisitions - The company completed a reverse merger with Angion Biomedica Corp. on June 1, 2023, resulting in approximately 9.7 million shares of common stock outstanding[29]. - Following the merger, Former Elicio equity holders owned approximately 65.2% of the company on a fully diluted basis[29]. - The merger between Former Elicio and Angion was completed on June 1, 2023, with Former Elicio being the accounting acquirer, resulting in the issuance of 5,375,751 shares of Angion common stock to Former Elicio stockholders[73]. - The company recognized net assets acquired from the merger, totaling $32.13 million, which included cash and cash equivalents of $24.00 million and other current assets of $540,000[76]. Internal Controls and Compliance - The company identified material weaknesses in internal control over financial reporting, including insufficient resources with knowledge of U.S. GAAP[209]. - Remediation efforts for identified material weaknesses are ongoing, but have not been fully remediated as of September 30, 2024[210]. - The effectiveness of the internal control over financial reporting is subject to inherent limitations, providing only reasonable assurance rather than absolute assurance[211]. - The company is engaging SEC compliance and technical accounting consultants to ensure conformity with U.S. GAAP[212]. - Additional finance and accounting personnel are being hired to enhance resources for complex accounting matters and financial reporting[212]. Legal and Regulatory - There is no current litigation that is expected to have a material adverse effect on the business, although future litigation outcomes remain uncertain[215].